within Pharmacolibrary.Drugs.ATC.N;

model N02CA51
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.055,
    k12             = 2.2,
    k21             = 2.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CA51</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dihydroergotamine is a semisynthetic ergot alkaloid used primarily for the acute treatment of migraine and cluster headaches. It acts as an agonist or partial agonist at several serotonin, adrenergic, and dopaminergic receptors. Some preparations contain dihydroergotamine in combination with other substances to enhance therapeutic effect. It is still approved and used today, mainly as a second-line migraine treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects (both sexes), intravenous administration.</p><h4>References</h4><ol><li><p>Schran, HF, et al., &amp; Hirsh, J (1983). The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. <i>Thrombosis research</i> 31(1) 51–67. DOI:<a href=&quot;https://doi.org/10.1016/0049-3848(83)90007-5&quot;>10.1016/0049-3848(83)90007-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6612697/&quot;>https://pubmed.ncbi.nlm.nih.gov/6612697</a></p></li><li><p>Verstraete, M (1990). Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. <i>Drugs</i> 40(4) 498–530. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199040040-00003&quot;>10.2165/00003495-199040040-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1964634/&quot;>https://pubmed.ncbi.nlm.nih.gov/1964634</a></p></li><li><p>Ibbotson, T, &amp; Perry, CM (2002). Danaparoid: a review of its use in thromboembolic and coagulation disorders. <i>Drugs</i> 62(15) 2283–2314. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262150-00016&quot;>10.2165/00003495-200262150-00016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12381232/&quot;>https://pubmed.ncbi.nlm.nih.gov/12381232</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CA51;
